CD274 and neoplasm: Similarly, the CHECKMATE-648 trial showed that nivolumab plus chemotherapy in patients with PD-L1 tumor proportion score (TPS) ≥1% (equivalent to a low CPS threshold) achieved a median OS of 13.2 months versus 10.7 months with chemotherapy alone (HR 0.74, P=0.002) [14].